Arnold Renée J G, Tang Jun, Schrecker Joshua, Hild Cheryl
Arnold Consultancy & Technology, LLC, 15 West 72nd Street, 23rd Floor, New York, NY, 10023, USA.
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Drugs Real World Outcomes. 2018 Dec;5(4):217-224. doi: 10.1007/s40801-018-0143-z.
Aegis Sciences Corporation developed a test (InterACT Rx) that objectively and definitively identifies substances known to interact with drug-drug interaction-prone medications commonly prescribed in the treatment of chronic pain and behavioral health disorders. The objective of this study was to assess the severity of identified drug-drug interactions, the reduction in the frequency and severity of identified drug-drug interactions, and the impact of the test on healthcare utilization.
Patients with chronic pain, behavioral health disorders, or both who had one or more drug-drug interaction tests and one or more drug-drug interactions identified in the study period were included. Drug-drug interaction test results described the number and severity of interactions and detected substances involved in drug-drug interactions. Patients' electronic medical records were obtained to analyze outpatient visits and prescription medications. The cost of outpatient visits was based on the Medicare Physician Fee Schedule. Outcomes were compared between the pre- and post-study index periods to determine the impact of the drug-drug interaction test on patient care.
A total of 262 patients were included. The majority of drug-drug interactions detected (77.9%) at index were of moderate severity. The number of monthly all-cause and pain-related outpatient visits was reduced in the post-index period compared with the pre-index period (0.74-0.54 and 0.69-0.49, respectively). Associated costs were reduced from US$64.92 to US$51.20, and from US$62.42 to US$47.62, (p < 0.0001 for both) for all-cause and pain-related outpatient visits, respectively. Follow-up drug-drug interaction testing for 43 patients revealed that previously reported drug-drug interactions at the index test were no longer identified in the subsequent test for 39.5% of patients.
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider's insights, drive clinical decision making, and improve patient outcomes.
宙斯盾科学公司研发了一项检测（InterACT Rx），该检测能够客观且明确地识别出已知与常用于治疗慢性疼痛和行为健康障碍的易发生药物相互作用的药物相互作用的物质。本研究的目的是评估已识别出的药物相互作用的严重程度、已识别出的药物相互作用的频率和严重程度的降低情况，以及该检测对医疗保健利用的影响。
纳入在研究期间进行了一项或多项药物相互作用检测且识别出一种或多种药物相互作用的慢性疼痛、行为健康障碍或两者皆有的患者。药物相互作用检测结果描述了相互作用的数量和严重程度以及参与药物相互作用的检测物质。获取患者的电子病历以分析门诊就诊情况和处方药。门诊就诊费用基于医疗保险医师费率表。比较研究前和研究后指标期的结果，以确定药物相互作用检测对患者护理的影响。
共纳入262例患者。在指标期检测到的大多数药物相互作用（77.9%）为中度严重程度。与指标期前相比，指标期后每月全因和疼痛相关门诊就诊次数减少（分别为0.74 - 0.54和0.69 - 0.49）。全因和疼痛相关门诊就诊的相关费用分别从64.92美元降至51.20美元，以及从62.42美元降至47.62美元（两者p < 0.0001）。对43例患者进行的后续药物相互作用检测显示，在后续检测中，39.5%的患者未再识别出指标检测中先前报告的药物相互作用。
采用确定性检测来检测其相互作用可能导致药物不良事件的物质，可以增强医疗服务提供者的洞察力，推动临床决策制定，并改善患者结局。
